Today: 20 May 2026
Australia Stock Market Today: ASX 200 Falls Again as Inflation Shock Puts RBA Back in Focus
29 April 2026
2 mins read

Australia Stock Market Today: ASX 200 Falls Again as Inflation Shock Puts RBA Back in Focus

Sydney, April 29, 2026, 20:01 AEST

Australia’s share market finished in the red on Wednesday, dragging the S&P/ASX 200 down to levels last seen almost four weeks ago. A spike in inflation kept traders fixated on the Reserve Bank of Australia’s looming rate call. The benchmark gave up 23.7 points, or 0.27%, to close at 8,687—marking its seventh consecutive decline, the longest such streak since mid-2022.

This shift is key, with inflation once more dictating risk pricing for Australian stocks. According to the Australian Bureau of Statistics, the consumer price index climbed 4.6% over the twelve months to March—an acceleration from February’s 3.7%, marking the highest level since September 2023. The trimmed mean, which excludes outsized moves, stayed at 3.3%.

The Reserve Bank of Australia’s cash rate target holds steady at 4.10%, with policymakers set to decide again on May 5 at 2:30 p.m. AEST. Following the latest inflation numbers, traders slashed the odds of a May hike—implied probability dropped to roughly 71% from 86%. Still, markets are geared up for a live call next week.

“March inflation landed on the high side, though it didn’t quite overshoot the worst forecasts,” said IG market analyst Tony Sycamore. The headline and trimmed mean readings are both still above the RBA’s 2%–3% target midpoint, he noted, which keeps the odds high for a 25 basis-point hike to 4.35% at the central bank’s meeting next week. AAP News

Kai Chen, director at MPC Markets, described the market’s move as “relief versus feared worse” after the ASX pared back its earlier drop. Still, he argued, nothing fundamental had shifted on inflation: “Without a genuine resolution, oil stays elevated, services inflation stays sticky, and the RBA stays hawkish into H2.” The Economic Times

Gains in utilities, up 2.18%, and energy, which added 1.27%, stood out. But health care dropped 1.36%, financials edged down 0.61%, and materials lost 0.38%. Despite those declines, MarketIndex noted that advancers just managed to outnumber decliners on the wider S&P/ASX 300.

BHP, Fortescue, and Rio Tinto all slipped as a stronger U.S. dollar and rising oil prices hurt commodity sentiment. The materials index trimmed some of its declines but still finished roughly 0.4% lower.

Banks pulled the index down too. According to AAP, financials slipped 0.6%. Commonwealth Bank weighed on the sector, and three of the big four banks dropped, while ANZ bucked the trend, climbing after its deal to acquire the rest of French partner Worldline in their payments JV. “An important barometer for borrower resilience and the health of the broader economy,” is how Sharesies head of capital markets Jacki Neumann described the upcoming round of bank results. AAP News

Energy names managed gains, with Woodside Energy climbing after first-quarter revenue topped forecasts—stronger realised prices compensated for output losses tied to cyclone disruptions. CEO Liz Westcott pointed out that because of lagged contract pricing, higher spot prices for LNG will boost results in quarters ahead.

Health care continued to lag. AAP noted CSL slid to lows not seen since August 2017, dragging the sector down 1.4%. Sellers kept up pressure after a rocky period for major health names, with Cochlear’s guidance downgrade still weighing on the mood.

But there’s risk in both directions. Should fuel prices drop quickly, or if the RBA judges that the oil shock isn’t spilling into wider price pressures, a pause is still on the table. Reuters quoted IG’s Sycamore, who noted that this view could catch on if the board feels the worst of the inflation scare is behind them. On the other side, the downside scenario looks more straightforward: a protracted energy squeeze risks keeping inflation above target and dragging rate-sensitive stocks back down.

The All Ordinaries slipped 19.3 points, or 0.22%, finishing at 8,915.7. Late trade saw the Australian dollar near 71.6 U.S. cents. Eyes now turn to U.S. rates overnight, with the RBA decision set for next Tuesday.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
FTSE 100 Falls Today as AstraZeneca and GSK Drag London Stocks Lower
Previous Story

FTSE 100 Falls Today as AstraZeneca and GSK Drag London Stocks Lower

US Stock Futures Today Pre-Market: Nasdaq Leads As Big Tech Earnings Put AI Rally To The Test
Next Story

US Stock Futures Today Pre-Market: Nasdaq Leads As Big Tech Earnings Put AI Rally To The Test

Go toTop